Trial updateRetina
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Recruiting. Phase 3. Registered enrolment: 561. AbbVie
Why it matters
Track this study through NCT07007065. No results are posted in this registry record.
The study at a glance
- Registry status
- Recruiting
- Phase
- Phase 3
- Registered enrolment
- 561
- Results posted
- No
- Sponsor
- AbbVie
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.
References (1)
Source date: 15 Sept 2026 · United States · Austria · Belgium · Bulgaria · Canada · Croatia · Czechia · France · Germany · Greece · Hungary · Israel · Italy · Portugal · Puerto Rico · Spain · United Kingdom